Cellomics Inc has released their Cyto-Cell Mem Translocation BioApplication Software (CCM) and PKC-alpha Activation HitKit Reagent Kit that, in combination with the ArrayScan HCS Reader, provide a comprehensive solution for cell-based discovery. The CCM BioApplication offers validated, "out of the box," functionality to quantify the movement of biomolecules between the cell cytoplasm and the plasma membrane, which may be applied to dissecting complex cellular responses to external stimuli or drug treatment. Monitoring the spatial redistribution of proteins over time is important for understanding the mechanisms underlying a broad array of human disease and represents one approach whereby pharmaceutical companies may expedite the discovery of new and more effective drug therapies.

"This (CCM) tool is an important advance for our portfolio of BioApplications," stated Dr. Jeffrey Haskins, Vice President of Assay Development at Cellomics. "The ability to investigate cytoplasm to membrane translocation of target molecules, a process that was previously limited by other imaging approaches, provides a powerful tool for selecting novel therapeutic compounds. These targets impact broad areas including cell signaling, cancer, and metabolic diseases."

In addition to enjoying a broad, functional appeal, the PKC-alpha Activation HitKit Reagent Kit expedites assay development and serves customers in validating the CCM BioApplication. It adds to a growing list of high content screening-qualified reagent kits that enable simultaneous monitoring of multiple targets in the same cell.

Cellomics is pioneering the field of cellular knowledge extraction. Its unique technology, referred to as High Content Screening, integrates fluorescent reagents, kits, cell lines, multi-parametric assays, HCS instrumentation (both fixed end-point and kinetics systems), and informatics tools to achieve a flexible, broadly applicable platform for users in the life sciences.

This automated platform, when applied to lead optimization, predictive toxicology, and new target validation, is proving to reduce the "idea-to-discovery" cycle time in drug discovery while increasing the probability of the therapeutic success of leads as well as reducing the cycle time in research and similar institutions.

Currently, Cellomics' proprietary ArrayScan and KineticScan HCS Readers, along with its vHCS Discovery Toolbox software and proprietary applications, are in use at multiple sites within the top fifteen pharmaceutical companies in the world, as well as several additional leading pharmaceutical and biotechnology companies and academic centers globally.